SCHEMBL7232273

SCHEMBL7232273

CN(Cc1ccccc1)C(=O)c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 14/20 0.73
MAPK11 Q15759 10/20 0.66
MAPK14 Q16539 10/20 0.66
MAPK13 O15264 9/20 0.66
MAPK12 P53778 9/20 0.66
TGFBR1 P36897 2/20 0.66
GCGR P47871 8/20 0.62
CSNK1A1 P48729 4/20 0.58
CSNK1D P48730 4/20 0.58
PRKD3 O94806 3/20 0.58
MAP4K4 O95819 3/20 0.58
FRK P42685 3/20 0.58
MAPK9 P45984 3/20 0.58
GSK3B P49841 3/20 0.58
PTK6 Q13882 3/20 0.58
CLK4 Q9HAZ1 2/20 0.58
PRKD2 Q9BZL6 2/20 0.58
RAF1 P04049 3/20 0.57
BRAF P15056 3/20 0.55
ALDH1A1 P00352 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4565990 0.85 ALOX5 (1.00) ALOX5MAPK11MAPK14MAPK13MAPK12
SCHEMBL4552013 0.80 ALOX5 (1.00) ALOX5MAPK11MAPK14MAPK13MAPK12
SCHEMBL413667 0.80 MAPK14 (1.00) ALOX5MAPK11MAPK14MAPK13MAPK12
SCHEMBL4552316 0.79 MAPK14 (1.00) ALOX5MAPK11MAPK14MAPK13MAPK12
SCHEMBL9195042 0.79 MAPK14 (1.00) ALOX5MAPK11MAPK14MAPK13MAPK12
SCHEMBL4566588 0.78 ALOX5 (0.67) ALOX5MAPK11MAPK14MAPK13MAPK12
SCHEMBL19868948 0.77 MAPK14 (1.00) ALOX5MAPK11MAPK14MAPK13MAPK12
SCHEMBL7164313 0.77 BRAF (0.56) ALOX5MAPK11MAPK14MAPK13MAPK12
SCHEMBL5078081 0.77 ALOX5 (0.76) ALOX5MAPK11MAPK14MAPK13MAPK12
SCHEMBL7228830 0.77 ALOX5 (1.00) ALOX5MAPK11MAPK14MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6645989-B2 Antiinflammatory agents SMITHKLINE BEECHAM CORPORATION 2003-11-11 US disclosed
US-20030064997-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2003-04-03 US disclosed
US-6268370-B1 CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2001-07-31 US disclosed
US-5916891-A CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1999-06-29 US disclosed
US-5686455-A Imidazole derivatives and their use as cytokine inhibitors SMITHKLINE BEECHAM CORPORATION (US) 1997-11-11 US disclosed
US-5656644-A CYTOKINE SUPPRESSORS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-12 US disclosed
EP-0623126-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1994-11-09 EP disclosed
WO-1993014081-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1993-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064997-A1 Novel compounds BRD4, BRDT, HDAC6 ALOX5 2555/4885MAPK11 2198/4885MAPK14 3769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.